Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera
Disc Medicine, Inc. (IRON)
Company Research
Source: GlobeNewswire
WATERTOWN, Mass., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to DISC-3405 for the treatment of patients with polycythemia vera (PV). “Orphan drug designation is an important milestone that highlights the potential of DISC-3405 in PV, a rare disease with few treatment options,” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc. “We look forward to sharing initial data from our ongoing Phase 1 trial of DISC-3405 in healthy volunteers in the first half of 2024.” FDA Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the United States. Orphan Drug
Show less
Read more
Impact Snapshot
Event Time:
IRON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRON alerts
High impacting Disc Medicine, Inc. news events
Weekly update
A roundup of the hottest topics
IRON
News
- Disc Medicine, Inc. (NASDAQ: IRON) had its price target raised by analysts at Stifel Nicolaus from $71.00 to $73.00. They now have a "buy" rating on the stock.MarketBeat
- Disc Medicine, Inc. (NASDAQ: IRON) had its price target lowered by analysts at Morgan Stanley from $75.00 to $40.00. They now have an "equal weight" rating on the stock.MarketBeat
- Disc Medicine, Inc. (NASDAQ: IRON) had its price target lowered by analysts at BMO Capital Markets from $80.00 to $50.00. They now have an "outperform" rating on the stock.MarketBeat
- Disc Medicine, Inc. (NASDAQ: IRON) had its price target lowered by analysts at Stifel Nicolaus from $104.00 to $71.00. They now have a "buy" rating on the stock.MarketBeat
- Attention Disc Medicine, Inc. Investors: Company Investigated by the Portnoy Law FirmGlobeNewswire
IRON
Earnings
- 11/9/23 - Beat
IRON
Sec Filings
- 5/3/24 - Form 4
- 5/1/24 - Form DEF
- 5/1/24 - Form ARS
- IRON's page on the SEC website